## GRIFOLS

Successfully Executing and Delivering on Commitments

**Q2 2023 Results** *July 27, 2023* 



### Legal Disclaimer

#### Important Information

This presentation does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Spanish Securities Market and Investment Services Law (Law 6/2023, of 17 March, as amended and restated from time to time), Royal Decree 1310/2005, of November 4, and its implementing regulations. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any other jurisdiction.

#### Forward-Looking Statements

This presentation contains forward-looking information and statements about GRIFOLS based on current assumptions and forecast made by GRIFOLS management, including pro forma figures, estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expected", "potential", "estimates" and similar expressions.

Although Grifols believes that the expectations reflected in such forward-looking statements are reasonable, various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the Company and the estimates given here. These factors include those discussed in our public reports filed with the Comisión Nacional del Mercado de Valores and the Securities and Exchange Commission, which are accessible to the public. The Company assumes no liability whatsoever to update these forward-looking statements or conform them to future events or developments. Forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of Grifols.

#### NON-GAAP Financial Measures

This presentation refers to certain non-GAAP financial measures. The presentation of these financial measures is not intended to be considered in isolation, or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. In addition, these measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparative purposes. We compensate for these limitations by providing specific information regarding GAAP amounts excluded from these non-GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in our Grifols Financial Statements.





## >>> 1. Our Turnaround Strategy

- 2. Performance by Business Unit
- 3. Group Financial Performance
- 4. Final Remarks
- 5. Annex



### *» Turnaround Strategy*

### Successfully Executing and Delivering on Commitments

Strong first half of 2023 backed by excellent execution, financial discipline and reinforced performance culture

Operational performance	<ul> <li>Double-digit revenues growth driven by Biopharma</li> <li>Adjusted EBITDA margin of 22.2% (23.4% in Q2'23)</li> <li>Operational improvement plan 100% deployed, leading to EUR 450m+ cash cost savings</li> <li>Plasma supply and cost per liter continue to gain momentum</li> </ul>	Sustainable growth
Guidance	<ul> <li>Revenues and adjusted EBITDA margin exceeded H1'23 guidance</li> <li>Raised H2'23 and FY23 guidance for revenues and adjusted EBITDA</li> </ul>	Margin expansion
Deleveraging	<ul> <li>Leverage ratio continues to decline as EBITDA improves</li> <li>Committed to 4x leverage ratio by end-2024</li> <li>Several workstreams in process</li> </ul>	Optimized capital allocation

Towards achieving

GRIFOLS


our goals

1. Our Turnaround Strategy


### >>> 2. Performance by Business Unit

- 5

- 3. Group Financial Performance
- 4. Final Remarks
- 5. Annex



## *Performance by Business Unit* **Revenue Growth Driven by Biopharma**



Grifols excl. Biotest 2,968	Biotest	Grifols incl. Biotest		
2,968				
	257	3,225		
+9.4%	+161.6%	+14.8%		
+7.7%	+162.5%	+13.1%		
2,441	257	2,698		
+10.2%	+161.6%	+16.7%		
+8.4%	+162.5%	+14.9%		
341	-	341		
+3.7%	-	+3.7%		
+3.0%	-	+3.0%		
83	-	83		
+57.2%	-	+57.2%		
+53.9%	-	+53.9%		
103	-	103		
-10.9%	- //	-10.9%		
-11.7%	-	-11.7%		
	+9.4% +7.7% 2,441 +10.2% +8.4% 341 +3.7% +3.0% 83 +57.2% +53.9% 103 -10.9%	+9.4%       +161.6%         +7.7%       +162.5%         2,441       257         +10.2%       +161.6%         +8.4%       +162.5%         341       -         +3.7%       -         +3.7%       -         +53.9%       -         103       -         -10.9%       -		

H1 2023

### » Performance by Business Unit | **Biopharma** (excl. Biotest)

### Key Plasma Proteins Show Significant Growth Led by Immunoglobulin

Q2'23	H1'23
+7.3% cc	+8.4% cc
+6.3%	+10.2%

	DUSI	ness line in H1'23 (at cc)	Com
of revenues	+13.6%	<ul> <li>Strong demand and positive pricing in the U.S. Important uptick in sales growth ex-U.S.</li> <li>Higher Xembify<sup>®</sup> (SCIG) demand in the U.S.</li> </ul>	• Initi con • Reg Xer
10-15% of revenues Albumin	+5.1%	<ul><li>Favorable pricing and higher demand in China and RoW</li><li>Partially offsetting lower demand in the U.S.</li></ul>	app cou Pol • Lau bug
25-30% of revenues Alpha-1 & Specialty proteins	+0.3%	<ul> <li>Higher alpha-1 volume in the U.S., partially offsetting lower volume in some European countries</li> <li>Strong anti-rabies' performance driven by higher demand and favorable customer mix in the U.S.</li> <li>Lower pdFVIII demand in U.S.</li> </ul>	• Sup EX in E • Vis and

#### Commercial milestones

- Initiation of Xembify<sup>®</sup> European commercialization, launched in Spain
- Repeat Use Procedure (RUP) for Xembify<sup>®</sup> to extend its registration for approval in 5 additional European countries (Denmark, Iceland, Norway, Poland and Portugal)
- Launch of direct-to-consumer Alpha-1 buccal swab in the U.S.
- Support Albumin in Egypt launch at EXCON congress; new Albumin license in Egypt
- Vistaseal<sup>™</sup>/Veraseal<sup>™</sup> launch in Korea and Switzerland

# Performance by Business Unit | Biopharma | Immunoglobulin Strengthening Our IG Franchise to Support Future Performance

Strong IG outlook

€14bn+ market

High-single-digit long-term growth

Primary and secondary immunodeficiencies gaining momentum

9-10% growth (2018-2025)1

40-55% of IG market uses

### Our growth strategy...

Focus on continued growth in U.S. and key ex-U.S. countries

Focus on large unmet medical need in immunodeficiency market and accelerate Xembify<sup>®</sup>'s adoption

- IG supply levels to meet customer demand
- Increased focus on improving diagnosis and treatment rates

and short-term catalysts (12-18 months)

- Launch of Xembify<sup>®</sup> pre-filled syringes
- Launch of Xembify<sup>®</sup> bi-weekly dosing
- Launch in Australia, Spain and other EU countries
- Pursue new indications



GRIFOLS

- Maintain leadership in neurology and acute care
- Gamunex<sup>®</sup> market launch in New Zealand and Italy targeting CIDP
- Gamunex<sup>®</sup> EU launch for new indication (MG severe exacerbation)
- Gamunex<sup>®</sup> EU launch for new indication (measles indication)

<sup>1</sup> Source: MRB Report Analysis of the 2018 IVIG/SCIG Market in the United States and 2025 Forecast

### » Performance by Business Unit | Biopharma | Innovation Achieved Innovation Milestones Expected in H1 and On Track for H2

Moved	Milestone	2023 t	iming	Status <sup>1</sup>	Details
	Finalize enrollment of the PRECIOSA study	H1	0	Ø	Enrollment completed in May (410 subjects) following a successful acceleration plan (avg ~20 pt/mo in the last 12Mo
	Alpha-1 AT 15% SC study advancement from single to repeat dose phase	H1		Ø	Progress within Ph1/2 study. Positive PK & Safety data for single dose enabled to move to repeat dose phase
New Product & Indication	First patient enrolled and treated in Xembify <sup>®</sup> SID-CLL study	H1	H2	•	US first sites active. Accelerating Europe activation
	GIGA564 IND submission		H2		IND preparation on track for submission
	GIGA2339 pre-IND submission		H2		Pre-IND preparation on track to receive FDA guidance
	Final results of Xembify <sup>®</sup> bi-weekly dosing study	H1		Ø	Positive results. FDA Submission planned for Q3'23
_ifecycle Management	Final results of IVIG-PEG study	H1		Ø	Positive results
_	Finalize enrolment of the SPARTA study	H1	H2	Ø	Ahead of schedule Enrolment completed in June (339 subjects)
	Trimodulin ESsCAPE trial study initiation	H1		Ø	First sites active
Biotest	Yimmugo <sup>®</sup> BLA FDA submission	H1		Ø	FDA submission completed in June
שוטופטו	Fibrinogen ADFIRST trial completed and top line study results		H2		Enrollment close to completion
	Cytotect PreCyssion trial last patient expected		H2		Enrollment ongoing

# » Performance by Business Unit | Diagnostic Blood Typing Solutions Driving Performance

Q2'23	H1'23 Reported	Adjusted				
+5.1% cc	+3.0% cc	-2.4% cc				
+3.3%	+3.7%	-2.1%				

#### *Revenue performance by business line in H1'23 (at cc)*

of revenues NAT Donor Screening	-2.6%	<ul> <li>Extended agreement up to 20 years with CTS; impact on pricing</li> <li>Partially offset by higher demand in Japan, Indonesia and Philippines</li> <li>Important contract renewals and continued expansion in Ireland, Spain, South Africa, and Eastern Europe among other geographies</li> </ul>
25-30% of revenues Blood Typing Solutions (BTS)	+7.0%	<ul> <li>Strong performance across regions, remarkably in U.S. on the back of contracts with large GPOs, IDNs, and commercial labs.</li> <li>Double-digit growth in Argentina, Brazil, Indonesia, and the Middle East</li> <li>Sales of Gel-card ramping up in volume and price</li> </ul>
15-20% of revenues Recombinant proteins	+23.8% -11.3% adjusted	<ul> <li>Diagnostic company commercial true-up partially offset by lower joint business profits</li> <li>Signed a 10-year supply agreement with Siemens</li> </ul>

#### **Commercial** milestones

- Launch of AlphaID<sup>™</sup> At Home Genetic Health Risk Service, the first-ever free direct-to-consumer program in the U.S cleared by FDA, to screen for genetic risk of alpha-1
- Signed a 10-year extension contract agreement with Licon, a Mexican company specializing in clinical diagnostics and transfusion medicine
- First IVDR certificates for our Diagnostic products classified in risk class D (highest level); includes al reagent red blood cells and some gel cards

### » Performance by Business Unit | **Bio Supplies Integration of Access Biologicals Continues to Bear Fruit**

Q2'23 H1'23 +41.1% cc +53.9% cc +40.1% +57.2%

Revenue performance by business line in H1'23 (at cc)

50-55% of revenues Bio Supplies Biopharma	+38.6%	<ul> <li>Cell Therapy portfolio expansion through Access Biologicals acquisition and Leukopaks consolidation in EU</li> <li>Grifols legacy business growth driven by new customers</li> </ul>
25-30% of revenues Bio Supplies Diagnostic	+102.7%	<ul> <li>Growth driven by broader portfolio from Access acquisition</li> <li>Improved margins of Blood derived products related to operational optimization plan</li> </ul>
20-25% of revenues Plasma hyperimmune sales to third parties	+45.3%	Higher sales due to phasing in existing contracts

- 1. Our Turnaround Strategy
- 2. Performance by Business Unit

## >>> 3. Group Financial Performance

- 4. Final Remarks
- 5. Annex

# *© Group Financial Performance* **Exceeded Revenue and EBITDA Guidance**

Revenues (H1'23) incl. Biotest	<b>€3,225m</b> +14.8%; <b>+13.1% cc</b>	Exceeding previous FY23 guidance - +8-10% cc - +10-12% cc
Adjusted EBITDA excl. Biotest	— 02'23 — H1'23 — €356m €655m 23.4% 22.2% — 𝔅 —	Exceeding H1'23 guidance - 21%+
Cash Flow Balance sheet	6.9X Leverage ratio <sup>1</sup> €1.2bn Liqu	uidity Positive Adj. Oper. Cash Flow <sup>2</sup>
Plasma	+12% Plasma supply <sup>3</sup> -20% Cost p	er liter (CPL) <sup>4</sup>
Operational Improvement Plan	<b>100%</b> deployment of the EUR 450m+ annualized cash cost saving	gs
Q2 2023 Results		<ul> <li><sup>1</sup> Consistently calculated based on the credit facilities agreement and including Biotest; <sup>2</sup> Excluding EUR B4m restructuring cash out <sup>3</sup> Jun 23 YTD vs. Jun 22 YTD (excl. Biotest); <sup>4</sup> Jun 23 vs. July 22 (U.S. data)</li> <li>13 -</li> </ul>


### » Group Financial Performance

### **Strong Second Quarter Supporting Sequential Financial Improvement**



- Backed by robust underlying demand, pricing and product mix led by SCIG
- Mid-to-high single-digit growth driven by Biopharma, following solid plasma supply

(EUR in millions)



Operating performance

- Sequential Adj. EBITDA expansion supported by:
  - Strong business performance
  - Operational improvement plan driving cash cost savings
  - Operational leverage


(EUR in millions)



Leverage ratio<sup>1</sup> Continuous commitment to debt reduction. ٠ targeting 4x leverage ratio by end of 2024 💑 Biotest investmen -2.1x 9.0x 8.6x 7.1x 7.0x 6.9x Q2'22 Q3'22 Q4'22 Q1'23 Q2'23

<sup>1</sup> Consistently calculated based on credit facilities agreement and incl. Biotest

### *Science of the second sector and the second sector and the second sector and the second sector and the second sec* **Adjusted EBITDA Continues to Expand Driven by Biopharma**



### *© Group Financial Performance* | *Operational Improvement Plan* Excellent Execution: 100% Deployment of the EUR 450m+ Annualized **Cash Cost Savings Initiatives**

### **Acceleration** of the initiatives' deployment

75% of initiatives are plasma-related, triggering cash savings first and subsequently booked in the P&L, following the 9-months inventory accounting of the plasma industry



# Scroup Financial Performance | Operational Improvement Plan Operational Improvement Plan Underpins Further Cost Per Liter Decline





CPL decline driven by initiatives framed in the Operational Improvement Plan

Jun'23 YTD vs. Jun'22 YTD

GRIFOLS

Plasma supply growth +12%

#### Main drivers as of H1'23

- $\checkmark$  Reduction of donor commitment compensation
- ✓ Plasma-center network rationalization
- ✓ Staffing optimization

#### Main drivers going forward


 Reduction of other plasma costs resulting from process optimization, streamlined operations and overheads, lean processes and digitalization

Note: all figures compared with July'22 peak; 20% taking Jun'23, 15% taking March'23 and 10% taking avg. Q4'22 (U.S. data)

#### *© Group Financial Performance* | *Operational Improvement Plan* from Q2'23 onwards Lower Cost per Liter Drives Incremental Margin Expansion ••••• Cost per liter (CPL) ----- Adjusted Gross Margin Biopharma (excl. Biotest) 250bps+ Base 100 in H2'23 vs. H1'23 105 ----100 $\checkmark$ CPL $\rightarrow$ $\blacktriangle$ Gross margin 95 9-month lag to gross margin impact mostly coming into the P&L in 2024 90 85 Q2'23 Q2'22 Q4'22 01'23 O1'22 Q3'22 Q3'23 Q4'23

Graph for **illustrative purposes** 

## Scroup Financial Performance | Leverage Ratio EBITDA Improvement and Transactions Support Deleveraging Path



<sup>1</sup> Leverage ratio calculated based on the credit facilities agreement and including Biotest and assuming a debt of ~EUR 9.5bn

### » *Guidance* Raising H2'23 and Full Year 2023 Guidance

— Revenue (at cc)		Previous	New	
Total revenue growth (incl. Biotest)	FY23	8-10%	10-12%	
Biopharma revenue growth (incl. Biotest)	FY23	10-12%	12-14%	
		Previous	New	
EBITDA Adjusted Margin	H2'23	23-25%	24-25%	
(excl. Biotest)	FY23	22-24%	24%	
EBITDA Adjusted (incl. Biotest)	FY23	EUR 1.4bn+	EUR 1,400-1,450m	
Proforma EBITDA annualizing savings	FY23	EUR 1.7bn+	EUR 1,700-1,750m	
(excl. Biotest)		27-28%	28-29%	

- 1. Our Turnaround Strategy
- 2. Performance by Business Unit
- 3. Group Financial Performance

## >>> 4. Final Remarks

5. Annex



#### » Final Remarks

### **Executing on Key Levers in H2'23 to Meet Guidance**

Focused on accelerating the execution of the company's strategy; operational excellence; cash flow improvement and debt reduction

**22.2%** H1 2023 Exceeding 21%+ guidance 24-25%

H2 2023



#### Key levers

- Deliver strong sales growth driven by solid demand on key proteins, product and country mix
- Accelerate financial improvement backed by the Operational Improvement Plan
- Maintain strong growth on plasma supply; cost per liter (CPL) continues to decline
- Excel commercial and innovation execution strengthening IG franchise and alpha-1
- Focus on reducing leverage to 4x by end of 2024

Adj. EBITDA guidance (excl. Biotest)

**20.7%** H1 2022

**20.4%** H2 2022

- 1. Our Turnaround Strategy
- 2. Performance by Business Unit
- 3. Group Financial Performance
- 4. Final Remarks





## Sustainability | Our Sustainability Plan Ambition Setting our Sustainability Roadmap and Commitment with SDGs






Scientific progress that, guided by our pioneering spirit, addresses the needs of patients and protects the rights, safety and well-being of clinical-trial participants



## Sustainability | Progress in H1 2023 Donors, Patients and Our People Are at the Core of Our Sustainability



Sustainability | Progress in H1 2023
Making Steady Progress on Positive Impact on Environment and Society



## Sustainability | Progress in H1 2023 Ethical Leadership is in Our DNA

### Supply Chain: Mitigating Supplier Key Risks and Impacts

### Global Procurement Policy

- Integration of ESG factors into purchasing decisions
- Supplier selection and onboarding qualification includes on ESG performance





Incentive plans including ESG criteria

+ New short-term incentive plan for the entire workforce

New long-term incentive plan

Grifols has been awarded a Gold Medal by EcoVadis





- 1. Our Turnaround Strategy
- 2. Performance by Business Unit
- 3. Group Financial Performance
- 4. Final Remarks







	Q2 2023		Q2 2022			% vs PY				
	Grifols	Biotest	Grifols incl.	Grifols	Biotest	Grifols incl.	Grifols excl	. Biotest	Grifols incl.	Biotest
In thousands of euros	GINOIS	DIOLESI	Biotest	Ginots	Diotest	Biotest	Reported	At cc*	Reported	At cc*
Revenue by Business Unit	1,523,577	139,881	1,663,458	1,444,613	98,287	1,542,900	5.5%	6.5%	7.8%	8.8%
Biopharma	1,267,643	139,881	1,407,524	1,192,095	98,287	1,290,382	6.3%	7.3%	9.1%	10.0%
Diagnostic	165,013	-	165,013	159,687	-	159,687	3.3%	5.1%	3.3%	5.1%
Bio Supplies	40,349	-	40,349	28,806	-	28,806	40.1%	41.1%	40.1%	41.1%
Others & intersegments	50,572	-	50,572	64,025	-	64,025	(21.0%)	(20.6%)	(21.0%)	(20.6%)
Revenue by Country	1,523,577	139,881	1,663,458	1,444,613	98,287	1,542,900	5.5%	6.5%	7.8%	8.8%
US + CANADA	979,313	-	979,313	967,557	1,165	968,722	1.2%	2.0%	1.1%	1.8%
EU	248,529	73,342	321,871	214,521	50,334	264,855	15.9%	15.8%	21.5%	21.5%
ROW	295,735	66,539	362,274	262,535	46,788	309,323	12.6%	15.6%	17.1%	19.8%

\* Constant currency (cc) excludes exchange rate fluctuations over the period.



	H1 2023		H1 2022			% vs PY				
	Grifols	Biotest	Grifols incl.	Grifols	Biotest	Grifols incl.	Grifols excl	. Biotest	Grifols incl.	Biotest
In thousands of euros	Ginots	DIOLESI	Biotest	Ginots	Diotest	Biotest	Reported	At cc*	Reported	At cc*
Revenue by Business Unit	2,967,827	257,119	3,224,946	2,711,805	98,287	2,810,092	9.4%	7.7%	14.8%	13.1%
Biopharma	2,441,096	257,119	2,698,215	2,214,603	98,287	2,312,890	10.2%	8.4%	16.7%	14.9%
Diagnostic	341,488	-	341,488	329,436	-	329,436	3.7%	3.0%	3.7%	3.0%
Bio Supplies	82,615	-	82,615	52,553	-	52,553	57.2%	53.9%	57.2%	53.9%
Others & intersegments	102,628	-	102,628	115,213	-	115,213	(10.9%)	(11.7%)	(10.9%)	(11.7%)
Revenue by Country	2,967,827	257,119	3,224,946	2,711,805	98,287	2,810,092	9.4%	7.7%	14.8%	13.1%
US + CANADA	1,921,960	904	1,922,864	1,815,818	1,165	1,816,983	5.8%	3.4%	5.8%	3.4%
EU	489,123	138,408	627,531	423,289	50,334	473,623	15.6%	15.4%	32.5%	32.4%
ROW	556,744	117,807	674,551	472,698	46,788	519,486	17.8%	17.6%	29.8%	29.8%

\* Constant currency (cc) excludes exchange rate fluctuations over the period.

# Annex P&L | Q2 2023

	Q2 2023						Q2 2022		% vs PY					
	Gr	fols excl. Biote	st		Grifols incl. Biotest			Grifols incl. Biotest			Grifols excl. Biotest		Grifols inc	
In thousands of euros	Reported	One-offs	Reported excl. One-offs	Biotest	Reported	One-offs	Reported excl. One-offs	Grifols	Biotest	Combined	Reported	Reported excl. One- offs	Reported	Reported excl. One- offs
Net Revenue	1,523,577	-	1,523,577	139,881	1,663,458	-	1,663,458	1,444,613	98,287	1,542,899	5.5%	5.5%	7.8%	7.8%
Cost of Sales	(936,596)	1,597	(934,998)	(108,395)	(1,044,991)	1,597	(1,043,394)	(890,293)	(74,656)	(964,949)	5.2%	5.0%	8.3%	8.1%
Gross Margin	586,981	1,597	588,579	31,486	618,467	1,597	620,064	554,320	23,631	577,950	5.9%	6.2%	7.0%	7.3%
% Net revenue	38.5%		38.6%	22.5%	37.2%		37.3%	38.4%	24.0%	37.5%				
R&D	(72,479)	1,271	(71,208)	(16,114)	(88,593)	1,271	(87,322)	(75,372)	(9,755)	(85,127)	(3.8%)	(5.5%)	4.1%	2.6%
SG&A	(276,281)	7,381	(268,900)	(23,219)	(299,500)	7,381	(292,119)	(293,916)	(14,557)	(308,473)	(6.0%)	(8.5%)	(2.9%)	(5.3%)
Operating Expenses	(348,760)	8,652	(340,108)	(39,333)	(388,093)	8,652	(379,441)	(369,288)	(24,312)	(393,600)	(5.6%)	(7.9%)	(1.4%)	(3.6%)
Other Income	-	-	-	-		-	-	925	-	925	-	-	(100%)	0.0%
Share of Results of Equity Accounted Investees - Core Activities	13,022	-	13,022	-	13,022	-	13,022	80,096	-	80,096	(83.7%)	(83.7%)	(83.7%)	(83.7%)
OPERATING RESULT (EBIT)	251,243	10,250	261,493	(7,847)	243,396	10,250	253,646	266,054	(682)	265,371	(5.6%)	(1.7%)	(8.3%)	(4.4%)
% Net revenue	16.5%	-	17.2%	(5.6%)	14.6%	-	15.2%	18.4%	(0.7%)	17.2%				
Financial Result	(128,267)	-	(128,267)	(11,109)	(139,376)	-	(139,376)	(116,099)	(3,281)	(119,380)	10.5%	10.5%	16.8%	16.8%
Share of Results of Equity Accounted Investees	(801)	-	(801)	-	(801)	-	(801)	(271)	-	(271)	195.8%	195.8%	195.8%	195.8%
PROFIT BEFORE TAX	122,175	10,250	132,425	(18,956)	103,219	10,250	113,469	149,684	(3,961)	145,722	(18.4%)	(11.5%)	(29.2%)	(22.1%)
% Net revenue	8.0%	-	8.7%	(13.6%)	6.2%	-	6.8%	10.4%	(4.0%)	9.4%				
Income Tax Expense	(19,212)	(2,521)	(21,733)	5,864	(13,348)	(2,521)	(15,869)	(29,558)	(1,246)	(30,804)	(35.0%)	(26.5%)	(56.7%)	(48.5%)
% of pre-tax income	15.7%	-	16.4%	30.9%	12.9%	-	14.0%	19.7%	(31.5%)	21.1%				
CONSOLIDATED PROFIT	102,963	7,729	110,692	(13,092)	89,871	7,729	97,600	120,126	(5,207)	114,918	(14.3%)	(7.9%)	(21.8%)	(15.1%)
Results Attributable to Non-Controlling Interests	(33,392)	262	(33,130)	(4,434)	(37,826)	262	(37,564)	(25,907)	1,328	(24,578)	28.9%	27.9%	53.9%	52.8%
GROUP PROFIT	69,571	7,991	77,562	(17,527)	52,044	7,991	60,035	94,219	(3,879)	90,339	(26.2%)	(17.7%)	(42.4%)	(33.5%)
% Net revenue	4.6%		5.1%	(12.5%)	3.1%	0.0%	3.6%	6.5%	(3.9%)	5.9%				

# Annex P&L | H1 2023

	H1 2023						H1 2022		% vs PY					
	Gri	fols excl. Biotes	st		Gr	rifols incl. Biotest		Grifols incl. Biotest			Grifols exc		Grifols inc	
In thousands of euros	Reported	One-offs	Reported excl. One-offs	Biotest	Reported	One-offs	Reported excl. One-offs	Grifols	Biotest	Combined	Reported	Reported excl. One- offs	Reported	Reported excl. One- offs
Net Revenue	2,967,827	(18,830)	2,948,997	257,119	3,224,946	(18,830)	3,206,116	2,711,805	98,287	2,810,092	9.4%	8.7%	14.8%	14.1%
Cost of Sales	(1,851,156)	26,999	(1,824,157)	(200,883)	(2,052,039)	26,999	(2,025,040)	(1,662,885)	(74,656)	(1,737,541)	11.3%	9.7%	18.1%	16.5%
Gross Margin	1,116,671	8,169	1,124,840	56,236	1,172,907	8,169	1,181,076	1,048,920	23,631	1,072,551	6.5%	7.2%	9.4%	10.1%
% Net revenue	37.6%	-	38.1%	21.9%	36.4%	-	36.8%	38.7%	24.0%	38.2%				
R&D	(151,378)	5,041	(146,337)	(41,871)	(193,249)	5,041	(188,208)	(151,527)	(9,755)	(161,282)	(0.1%)	(3.4%)	19.8%	16.7%
SG&A	(666,229)	122,150	(544,079)	(46,931)	(713,160)	122,150	(591,010)	(553,333)	(14,557)	(567,890)	20.4%	(1.7%)	25.6%	4.1%
Operating Expenses	(817,607)	127,191	(690,415)	(88,802)	(906,409)	127,191	(779,218)	(704,860)	(24,312)	(729,172)	16.0%	(2.0%)	24.3%	6.9%
Other Income	-	-	-	-	-	-	-	4,508	-	4,508	-	-	(100%)	(100.0%)
Share of Results of Equity Accounted Investees - Core Activities	27,528	-	27,528	-	27,528	-	27,528	79,459	-	79,459	(65.4%)	(65.4%)	(65.4%)	(65.4%)
OPERATING RESULT (EBIT)	326,592	135,361	461,953	(32,566)	294,026	135,361	429,387	428,027	(681)	427,346	(23.7%)	7.9%	(31.2%)	0.5%
% Net revenue	11.0%	-	15.7%	(12.7%)	9.1%	-	13.4%	15.8%	(0.7%)	15.2%				
Financial Result	(251,992)	-	(251,992)	(22,126)	(274,118)	-	(274,118)	(195,472)	(3,281)	(198,753)	28.9%	28.9%	37.9%	37.9%
Share of Results of Equity Accounted Investees	(862)	-	(862)	-	(862)	-	(862)	(706)	-	(706)	22.1%	22.1%	22.1%	22.1%
PROFIT BEFORE TAX	73,737	135,361	209,098	(54,691)	19,046	135,361	154,407	231,849	(3,962)	227,887	(68.2%)	(9.8%)	(91.6%)	(32.2%)
% Net revenue	2.5%	-	7.1%	(21.3%)	0.6%	-	4.8%	8.5%	-	8.1%				
Income Tax Expense	(18,434)	(33,866)	(52,300)	8,315	(10,119)	(33,866)	(43,985)	(50,029)	(1,246)	(51,275)	(63.2%)	4.5%	(80.3%)	(14.2%)
% of pre-tax income	25.0%	-	25.0%	15.2%	53.1%	-	28.5%	21.6%	0.5%	22.5%				
CONSOLIDATED PROFIT	55,303	101,495	156,798	(46,376)	8,927	101,495	110,422	181,820	(5,208)	176,612	(69.6%)	(13.8%)	(94.9%)	(37.5%)
Results Attributable to Non-Controlling Interests	(66,801)	4,164	(62,637)	1,653	(65,148)	4,164	(60,983)	(34,292)	1,328	(32,963)	94.8%	82.7%	97.6%	85.0%
GROUP PROFIT	(11,498)	105,660	94,162	(44,723)	(56,221)	105,660	49,439	147,529	(3,880)	143,649	(107.8%)	(36.2%)	(139.1%)	(65.6%)
% Net revenue	(0.4%)	-	3.2%	(17.4%)	(1.7%)	-	1.5%	5.4%	-	5.1%				

# *Annex* **Cash Flow | Q2 2023**

	Q2 2023								Q2 2022	%	vs PY		
			Grifols exc	l. Biotest					Grifols incl. Biotest		Grifols incl. Biotest	Grifols in	ncl. Biotest
In thousands of euros	Reported	Restructuring costs	Transaction costs	Diagnostic true-up commercial	Total one-offs	Reported excl. One-offs	Biotest	Reported	Total one-offs	Reported excl. One-offs	Reported	Reported	Reported exe One-offs
Reported Group Profit	69,571	429	7,562	-	7,991	77,562	(17,527)	52,044	7,991	60,036	90,339	-42%	- 34%
Depreciation and Amortization	93,971	-	-	-	-	93,971	12,645	106,615	-	106,615	98,842	8%	8%
Net Provisions	8,592	4,867	-		4,867	13,459	(3,166)	5,425	4,867	10,292	1,975	175%	421%
Other Adjustments and Other Changes in Working Capital	(73,015)	(262)	2,520	-	2,258	(70,757)	(55)	(73,070)	2,258	(70,812)	(63,075)	16%	12%
Change in Operating Working Capital	(107,796)	3,946	-	-	3,946	(103,850)	(25,491)	(133,287)	3,946	(129,341)	(131,505)	1%	-2%
Changes in Inventories	(28,138)	-	-		-	(28,138)	(26,837)	(54,976)	-	(54,976)	(109,342)	-50%	- 50%
Change in Trade Receivables	(1,830)	-	-	-	-	(1,830)	(21,800)	(23,630)	-	(23,630)	(80,445)	- 71%	- 71%
Change in Trade Payables	(77,827)	3,946	-		3,946	(73,881)	23,146	(54,681)	3,946	(50,735)	<i>58,282</i>	-	
Net Cash Flow From Operating Activities	(8,677)	8,980	10,083	-	19,062	10,386	(33,595)	(42,272)	19,062	(23,210)	(3,424)	-	
Business Combinations and Investments in Group Companies	-		-		-	-	-	-	-	-	(1,500,825)	-	-
CAPEX	(34,375)		-		-	(34,375)	(8,295)	(42,670)	-	(42,670)	(71,709)	-40%	- 40%
R&D/Other Intangible Assets	(16,166)	-	-		-	(16,166)	(3,712)	(19,878)	-	(19,878)	(9,760)	104%	104%
Other Cash Inflow / (Outflow)	(34,455)	-	-		-	(34,455)	47,169	12,714	-	12,714	(33,515)	-138%	-138%
Net Cash Flow From Investing Activities	(84,996)		-	-	-	(84,996)	35,162	(49,834)	-	(49,834)	(1,615,809)	-97%	- 97%
Free Cash Flow	(93,673)	8,980	10,083	-	19,062	(74,611)	1,567	(92,106)	19,062	(73,044)	(1,619,233)	- 94%	- 95%
ssue / /Repayment) of Debt	194,918		-		-	194,918	(1,328)	193,591	-	193,591	(5,867)	-	-
Capital Grants	42	-	-		-	42	-	42	-	42	(447,431)	-	
Dividends (Paid) / Received	-	-	-		-	-	-	-	-	-	1,764	-	
Other Cash Flows From / (Used in) Financing Activities	(3,826)	-	-		-	(3,826)	133	(3,692)	-	(3,692)	10,616	-135%	- 135%
Net Cash Flow From Financing Activities	191,134	-	-	-	-	191,134	(1,195)	189,940	-	189,940	(440,918)	-	
Total Cash Flow	97,460	8,980	10,083	-	19,062	116,523	372	97,834	19,062	116,896	(2,060,151)	-105%	- 106%
Cash and Cash Equivalents at the Beginning of the Year	357,698				-	357,698	67,956	425,655	-	425,655	2,552,357	-	-
Effect of Exchange Rate Changes in Cash and Cash Equivalents	(111)	-			-	(111)	(24)	(137)	-	(137)	32,887	-100%	- 100%
Cash and Cash Equivalents at the End of the Period	455,048	8,980	10,083	-	19,062	474,110	68,304	523,352	19,062	542,414	525,094	0%	3%

# *Annex* Cash Flow | H1 2023

	H1 2023								1H 2022	22 % vs PY			
			Grifols ex	cl. Biotest					Grifols incl. Biotest		Grifols incl. Biotest	Grifols i	ncl. Biotest
In thousands of euros	Reported	Restructuring costs	Transaction costs	Diagnostic true-up commercial	Total one-offs	Reported excl. One-offs	Biotest	Reported	Total one-offs	Reported excl. One-offs	Reported	Reported	Reported excl. One-offs
Reported Group Profit	(11,498)	104,144	10,948	(9,432)	105,660	94,162	(44,723)	(56,221)	105,660	49,439	143,649	-139%	-66%
Depreciation and Amortization	189,568	-	-	-	-	189,568	36,860	226,428	-	226,428	187,208	21%	21%
Net Provisions	75,073	(34,112)	-	-	(34,112)	40,961	768	75,840	(34,112)	41,728	10,167	646%	310%
Other Adjustments and Other Changes in Working Capital	(56,197)	35,450	3,649	(9,398)	29,701	(26,495)	5,300	(50,896)	29,701	(21,194)	(67,958)	- 25%	-69%
Change in Operating Working Capital	(229,827)	(21,963)	-	18,830	(3,133)	(232,959)	(69,059)	(298,886)	(3,133)	(302,019)	(241,535)	24%	25%
Changes in Inventories	(137,595)	-	-		-	(137,595)	(60,631)	(198,226)	-	(198,226)	(228,441)	-13%	-13%
Change in Trade Receivables	(61,094)	-	-	18,830	18,830	(42,264)	(24,552)	(85,646)	18,830	(66,816)	(44,810)	91%	49%
Change in Trade Payables	(31,138)	(21,963)	-		(21,963)	(53,101)	16,124	(15,014)	(21,963)	(36,977)	<i>31,716</i>	-	
Net Cash Flow From Operating Activities	(32,880)	83,519	14,598		98,116	65,236	(70,854)	(103,735)	98,116	(5,618)	31,531	-	1.1
Business Combinations and Investments in Group Companies	-	-		-	-	-	-	-	-	-	(1,545,046)	-	
CAPEX	(71,834)	-	-		-	(71,834)	(13,575)	(85,408)	-	(85,408)	(123,975)	- 31%	-31%
R&D/Other Intangible Assets	(32,559)	-	-	-	-	(32,559)	(8,112)	(40,671)	-	(40,671)	(19,066)	113%	113%
Other Cash Inflow / (Outflow)	(53,448)	-	-		-	(53,448)	46,657	(6,792)	-	(6,792)	(108,965)	-94%	-94%
Net Cash Flow From Investing Activities	(157,841)		-	-	-	(157,841)	24,970	(132,871)	-	(132,871)	(1,797,052)	-93%	-93%
Free Cash Flow	(190,721)	83,519	14,598	•	98,116	(92,605)	(45,884)	(236,605)	98,116	(138,489)	(1,765,521)	-87%	-92%
Issue / /Repayment) of Debt	217,978	-	-	-	-	217,978	(2,504)	215,475	-	215,475	-	-	
Capital Grants	1,367	-	-	-	-	1,367	-	1,367	-	1,367	(447,431)	-	
Dividends (Paid) / Received	-	-	-	-	-	-	-	-	-	-	3,927	-	
Other Cash Flows From / (Used in) Financing Activities	2,105	-		-	-	2,105	-	2,105	-	2,105	10,816	-81%	-81%
Net Cash Flow From Financing Activities	221,451	-		-	-	221,451	(2,504)	218,947		218,947	(432,688 <mark>)</mark>	-	
Total Cash Flow	30,729	83,519	14,598	-	98,116	128,846	(48,388)	(17,659)	98,116	80,458	(2 <mark>,198,2</mark> 09)	- 99%	-104%
Cash and Cash Equivalents at the Beginning of the Year	431,337	-			-	431,337	116,642	547,979	-	547,979	2,675,611	- 80%	-80%
Effect of Exchange Rate Changes in Cash and Cash Equivalents	(7,018)				-	(7,018)	50	(6,968)	-	(6,968)	47,692	-115%	-115%
Cash and Cash Equivalents at the End of the Period	455,048	83,519	14,598	-	98,116	553,164	68,304	523,352	98,116	621,469	525,094	0%	18%

## Annex Balance Sheet | H1 2023

#### In thousands of euros

#### Assets June 2023 December 2022 16.627.972 Non-Current Assets 16.880.390 Goodwill and Other Intangible Assets 10,646,776 10,858,608 Property Plant & Equipment 3,225,684 3.270.937 1,905,591 1,955,177 Investments in Equity Accounted Investees Non-Current Financial Assets 630.453 620.745 Other Non-Current Assets 219,468 174,923 4,804,772 Current Assets 4,653,587 Non-Current Contract Assets Held for Sale 4,969 -Inventories 3.317.448 3.201.357 44,146 Current Contract Assets 35,154 Trade and Other Receivables 821,562 738,651 Other Current Financial Assets 33.883 43.663 64,381 Other Current Assets 81.814 Cash and Cash Equivalents 523,352 547.979 21,432,744 21,533,977 Total Assets

Liabilities	01/10/2	and the
	June 2023	December 2022
Equity	8,223,565	8,457,544
Capital	119,604	119,604
Share Premium	910,728	910,728
Reserves	4,529,237	4,326,436
Treasury StocL	(158,692)	(162,220)
Current Year Earnings	(56,221)	208,279
Other Comprehensive Income	517,162	727,111
Non-Controllling Interests	2,361,747	2,327,606
No-Current Liabilities	11,332,195	11,120,586
Non-Current Financial Liabilities	10,202,587	9,960,562
Other Non-Current Liabilities	1,129,608	1,160,024
Current Liabilities	1,876,984	1,955,847
Current Financial Liabilities	733,269	795,686
Other Current Liabilities	1,143,715	1,160,161
Total Equity and Liabilities	21,432,744	21,533,977

### » Annex EBIT to Adjusted EBITDA LTM Excl. Biotest | Q2 2023

					Q2 2023	
In thousand of euros	Q2 2023	Q1 2023	Q4 2022	Q3 2022	LTM	Q2 2022
OPERATING RESULT (EBIT)	251,243	75,348	173,747	211,271	711,609	266,054
Depreciation & Amortization	(94,936)	(98,296)	(102,226)	(98,047)	(393,505)	(93,950)
Reported EBITDA	346,180	173,644	275,973	309,318	1,105,115	360,004
% Net revenue	22.7%	12.0%	17.7%	21.6%	18.9%	24.9%
Restructuring costs	-	139,427	26,231	5,655	171,313	2,268
Transaction costs	9,735	4,515	696	505	15,451	15,310
Diagnostic commercial true-up	-	(18,830)	-	-	(18,830)	-
Access Biologicals gain	-	-	-	-	-	(72,984)
Divestment gain	-	-	-	(14,678)	(14,678)	-
Impairments	-	-	2,700	-	2,700	
Other non-recurring items	-	-	10,487	-	10,487	-
Total adjustments	9,735	125,112	40,114	(8,518)	166,443	(55,406)
Adjusted EBITDA	355,915	298,756	316,087	300,800	1,271,558	304,598
% Net revenue	23.4%	21.0%	20.3%	21.0%	21.8%	21.1%

### » Annex EBIT to Adjusted EBITDA LTM Incl. Biotest | Q2 2023

					Q2 2023	
In thousand of euros	Q2 2023	Q1 2023	Q4 2022	Q3 2022	LTM	Q2 2022
OPERATING RESULT (EBIT)	243,396	50,629	176,947	201,387	672,359	265,372
Depreciation & Amortization	(107,581)	(122,511)	(117,406)	(106,973)	(454,472)	(100,380)
Reported EBITDA	350,977	173,140	294,353	308,360	1,126,831	365,752
% Net revenue	21.1%	11.1%	17.2%	20.0%	17.4%	23.7%
Restructuring costs	-	139,427	26,231	5,655	171,313	2,268
Transaction costs	9,735	4,515	696	505	15,451	15,310
Diagnostic commercial true-up	-	(18,830)	-	-	(18,830)	-
Access Biologicals gain	-	-	-	-	-	(72,984)
Divestment gain	-	-	-	(14,678)	(14,678)	-
Impairments	-	-	2,700	-	2,700	
Biotest Next Level project	-	-	13,482	22,341	35,823	14,194
Other non-recurring items	-	-	10,487	-	10,487	
Total adjustments	9,735	125,112	53,596	13,823	202,266	(41,212)
Adjusted EBITDA	360,712	298,252	347,949	322,183	1,329,097	324,540
% Net revenue	21.7%	19.3%	20.3%	20.9%	20.6%	21.0%

# Annex Reconciliation Group Profit Reported to Adjusted | Q2 2023

	Report	ed			Adjust	tments			Adjuste	d
In thousand of euros	Excl. Biotest	Incl. Biotest	Restructuring costs	Transaction costs	Diagnostic commercial true-up	Amortization of deferred financial expenses	Amortization of intangible assets acquired in business combinations	IFRS 16	Excl. Biotest	Incl. Biotest
Net Revenue	1,523,577	1,663,458	-	-	-	-	-	-	1,523,577	1,663,458
Cost of Sales	(936,596)	(1,044,991)	1,597	-	-	-	-	(1,525)	(936,524)	(1,044,919)
Gross Margin	586,981	618,467	1,597	-	-	-	-	(1,525)	587,053	618,539
R&D	(72,479)	(88,593)	1,272	-	-	-	3,455	(96)	(67,849)	(83,962)
SG&A	(276,281)	(299,500)	(2,702)	10,083	-	-	12,020	(1,372)	(258,252)	(281,471)
Operating Expenses	(348,760)	(388,093)	(1,431)	10,083	-	-	15,475	(1,468)	(326,101)	(365,434)
Other Income	-	-	-	-	-	-	-	-	-	-
Share of Results of Equity Accounted Investees - Core Activities	13,022	13,022	-	-	-	-	-	-	13,022	13,022
OPERATING RESULT (EBIT)	251,243	243,396	167	10,083	-	-	15,475	(2,993)	273,975	266,128
Financial Result	(128,267)	(139,376)	-	-	-	14,326	-	10,680	(103,261)	(114,370)
Share of Results of Equity Accounted Investees	(801)	(801)	-	-	-	-	-	-	(801)	(801)
PROFIT BEFORE TAX	122,175	103,219	167	10,083	-	14,326	15,475	7,687	169,913	150,957
Income Tax Expense	(19,212)	(13,348)	-	(2,520)	-	(3,127)	(3,817)	(1,921)	(30,598)	(24,735)
CONSOLIDATED PROFIT	102,963	89,871	167	7,562	-	11,199	11,658	5,7 <mark>65</mark>	139,315	126,222
Results Attributable to Non-Controlling Interests	(33,392)	(37,826)	262	-	-	-	-		(33,130)	(37,564)
GROUP PROFIT	69,571	52,044	429	7,562	-	11,199	11,658	5,765	106,185	88,659

#### » Annex **Reconciliation Group Profit Reported to Adjusted | Q2 2022**

	Report	ed			Adjust	ments			Adjuste	d
In thousand of euros	Excl. Biotest	Incl. Biotest	Restructuring costs	Transaction costs	Divestment gain	Amortization of deferred financial expenses	Amortization of intangible assets acquired in business combinations	IFRS 16	Excl. Biotest	Incl. Biotest
Net Revenue	1,444,613	1,542,899	-	-	-	-	-	-	1,444,613	1,542,899
Cost of Sales	(890,293)	(964,949)	484	-	-	-	861	(3,421)	(892,369)	(967,025)
Gross Margin	554,320	577,950	484	-	-	-	861	(3,421)	552,244	575,873
R&D	(75,372)	(85,127)	813	-	-	-	811	(731)	(74,478)	(84,234)
SG&A	(293,916)	(308,473)	971	18,075	-	-	10,087	(362)	(265,144)	(279,701)
Operating Expenses	(369,288)	(393,600)	1,785	18,075	-	-	10,898	(1,092)	(339,622)	(363,935)
Other Income	925	925	-	-	(4,508)	-	-	- 10 M -	(3,583)	(3,583)
Share of Results of Equity Accounted Investees - Core Activities	80,096	80,096	-	(72,984)	-	-	-	-	7,112	7,112
OPERATING RESULT (EBIT)	266,054	265,371	2,269	(54,909)	(4,508)	-	11,759	(4,514)	216,151	215,469
Financial Result	(116,099)	(119,380)	-	-	-	16,306	-	11,118	(88,675)	(91,956)
Share of Results of Equity Accounted Investees	(271)	(271)	-	-	-	-	-		(271)	(271)
PROFIT BEFORE TAX	149,684	145,722	2,269	(54,909)	(4,508)	16,306	11,759	6,605	127,205	123,243
Income Tax Expense	(29,558)	(30,804)	(567)	(4,405)	(0)	(3,223)	(2,472)	(1,319)	(41,545)	(42,791)
CONSOLIDATED PROFIT	120,126	114,918	1,701	(59,314)	(4,508)	13,082	9,287	5,286	85,660	80,452
Results Attributable to Non-Controlling Interests	(25,907)	(24,578)	-	-	-	-	(781)	- ///	(26,688)	(25,359)
GROUP PROFIT	94,219	90,339	1,701	(59,314)	(4,508)	13,082	8,506	5,286	58,973	55,093

#### » Annex **Reconciliation Group Profit Reported to Adjusted | H1 2023**

	Reporte	d			Adjust	tments			Adjusted	
In thousand of euros	Excl. Biotest	Incl. Biotest	Restructuring costs	Transaction costs	Diagnostic commercial true-up	Amortization of deferred financial expenses	Amortization of intangible assets acquired in business combinations	IFRS 16	Excl. Biotest	Incl. Biotest
Net Revenue	2,967,827	3,224,946	-	-	(18,830)	-	-	-	2,948,997	3,206,116
Cost of Sales	(1,851,156)	(2,052,039)	26,999	-	-	-	-	(5,189)	(1,829,346)	(2,030,229)
Gross Margin	1,116,671	1,172,907	26,999	-	(18,830)	-	-	(5,189)	1,119,651	1,175,887
R&D	(151,378)	(193,249)	5,042		-	-	18,987	(386)	(127,736)	(169,607)
SG&A	(666,229)	(713,160)	107,553	14,598	-	-	26,446	(2,744)	(520,376)	(567,307)
Operating Expenses	(817,607)	(906,409)	112,594	14,598	-	-	45,433	(3,130)	(648,112)	(736,914)
Other Income	-	-	-	-	-	-	-	-	-	-
Share of Results of Equity Accounted Investees - Core Activities	27,528	27,528	-	-	-	-	-	2	27,528	27,528
OPERATING RESULT (EBIT)	326,592	294,026	139,594	14,598	(18,830)	-	45,433	(8,319)	499,067	466,502
Financial Result	(251,992)	(274,118)	-	-	-	28,226	-	21,377	(202,389)	(224,515)
Share of Results of Equity Accounted Investees	(862)	(862)	-	-	-	-	-		(862)	(862)
PROFIT BEFORE TAX	73,737	19,046	139,594	14,598	(18,830)	28,226	45,433	13,058	295,816	241,124
Income Tax Expense	(18,434)	(10,119)	(34,924)	(3,649)	4,708	(6,179)	(11,577)	(3,264)	(73,321)	(65,006)
CONSOLIDATED PROFIT	55,303	8,927	104,670	10,948	(14,123)	22,047	33,856	9,7 <mark>93</mark>	222,495	176,119
Results Attributable to Non-Controlling Interests	(66,801)	(65,148)	(526)	-	4,690	-	(790)	- 10.00	(63,426)	(61,773)
GROUP PROFIT	(11,498)	(56,221)	104,144	10,948	(9,432)	22,047	33,066	9,793	159,068	114,346

#### » Annex **Reconciliation Group Profit Reported to Adjusted | H1 2022**

	Report	ed			Adjus	tments			Adjust	ed
In thousand of euros	Excl. Biotest	Incl. Biotest	Restructuring costs	Transaction costs	Divestment gain	Amortization of deferred financial expenses	Amortization of intangible assets acquired in business combinations	IFRS 16	Excl. Biotest	Incl. Biotest
Net Revenue	2,711,805	2,810,092	-	-	-	-	-	-	2,711,805	2,810,092
Cost of Sales	(1,662,885)	(1,737,541)	494	-	-	-	1,683	(6,693)	(1,667,401)	(1,742,057)
Gross Margin	1,048,920	1,072,551	494	-	-	-	1,683	(6,693)	1,044,404	1,068,035
R&D	(151,527)	(161,282)	1,994	-	-	-	1,619	(1,017)	(148,930)	(158,685)
SG&A	(553,333)	(567,890)	1,700	19,396	-	-	20,837	(688)	(512,087)	(526,644)
Operating Expenses	(704,860)	(729,172)	3,695	19,396	-	-	22,456	(1,704)	(661,018)	(685,329)
Other Income	4,508	4,508	-	-	(8,091)	-	-	-	(3,583)	(3,583)
Share of Results of Equity Accounted Investees - Core Activities	79,459	79,459	-	(72,984)	-	-	-	-	6,475	6,475
OPERATING RESULT (EBIT)	428,027	427,346	4,189	(53,588)	(8,091)	-	24,139	(8,398)	386,279	385,597
Financial Result	(195,472)	(198,753)	-	-	-	29,098	-	21,673	(144,702)	(147,982)
Share of Results of Equity Accounted Investees	(706)	(706)	-	-	-	-	-		(706)	(706)
PROFIT BEFORE TAX	231,849	227,887	4,189	(53,588)	(8,091)	29,098	24,139	13,276	240,871	236,909
Income Tax Expense	(50,029)	(51,275)	(1,047)	(4,735)	896	(6,446)	(5,388)	(2,987)	(69,737)	(70,983)
CONSOLIDATED PROFIT	181,820	176,612	3,141	(58,323)	(7,195)	22,651	18,751	10,289	171,135	165,927
Results Attributable to Non-Controlling Interests	(34,292)	(32,963)	-	-	-	-	(1,528)	- ///	(35,820)	(34,491)
GROUP PROFIT	147,529	143,649	3,141	(58,323)	(7,195)	22,651	17,223	10,289	135,315	131,436

## Leverage Ratio and Adj. EBITDA LTM as per Credit Agreement | H1 2023

Leverage Ratio as per Credit Agreeement	6.92x	7.14x	
Adjusted EBITDA LTM as per Credit Agreement	1,361	1,287	5.7%
Net Financial Debt*	9,422	9,191	2.5%
In millions of euros except ratio	H1 2023	FY 2022	% Var

\*Excludes the impact of IFRS 16

	H1 2023		
In million of euros	LTM	FY 2022	% Var
OPERATING RESULT (EBIT)	672	806	(16.6%)
Depreciation & Amortization	(454)	(415)	9.5%
Reported EBITDA	1,127	1,221	(7.7%)
IFRS 16	(101)	(100)	1.4%
Transaction costs	19	26	(26.4%)
Restructuring costs	171	36	374.5%
Cost savings, operating improvements and synergies on a "run rate"	121	100	21.0%
Other one-offs	24	4	595.5%
Total adjustments	234	66	253.4%
Adjusted EBITDA LTM as per Credit Agreement	1,361	1,287	5.7%



# Net Revenue Reconciliation Constant Currency Excl. Biotest | Q2 2023

In thousands of euros	Q2 2023	Q2 2022	% Var
Reported Net Revenues	1,523,577	1,444,613	5.5%
Variation due to Exchange Rate Effects	14,879		
Net Revenues at Constant Currency	1,538,456	1,444,613	6.5%
In thousands of euros	Q2 2023	Q2 2022	% Var
Reported Biopharma Revenues	1,267,643	1,192,095	6.3%
Variation due to Exchange Rate Effects	11,455		
Reported Biopharma Net Revenues at Constant Currency	1,279,098	1,192,095	7.3%
In thousands of euros	Q2 2023	Q2 2022	% Var
Reported U.S. + Canada Net Revenues	979,313	967,557	1.2%
Variation due to Exchange Rate Effects	7,145		
Reported U.S. + Canada Net Revenues at Constant Currency	986,458	967,557	2.0%
In thousands of euros	Q2 2023	Q2 2022	% Var
Reported EU Net Revenues	248,529	214,521	15.9%
Variation due to Exchange Rate Effects	(58)		
Reported EU Net Revenues at Constant Currency	248,471	214,521	15.8%
In thousands of euros	Q2 2023	Q2 2022	% Var
Reported ROW Net Revenues	295.735	262.535	12.6%
	7,792	202,535	12.0%
Variation due to Exchange Rate Effects			
Reported ROW Net Revenues at Constant Currency	303,527	262,535	15.6%



# Net Revenue Reconciliation Constant Currency Incl. Biotest | Q2 2023

In thousands of euros	Q2 2023	Q2 2022	% Var	In thousands of euros	Q2 2023	Q2 2022	% Var
Reported Net Revenues	1,663,458	1,542,900	7.8%	Reported Others & Intersegments Net Revenues	50,572	64,025	(21.0%)
Variation due to Exchange Rate Effects	15,204			Variation due to Exchange Rate Effects	283		
Net Revenues at Constant Currency	1,678,662	1,542,900	8.8%	Reported Other & Intersegments Net Revenues at Constant Currency	50,855	64,025	(20.6%)
In thousands of euros	Q2 2023	Q2 2022	% Var	In thousands of euros	Q2 2023	Q2 2022	% Var
Reported Biopharma Net Revenues	1.407.524	1.290.382	9.1%	Reported U.S. + Canada Net Revenues	979.313	968.722	1.1%
Variation due to Exchange Rate Effects	1,407,524	1,290,302	9.1%	Variation due to Exchange Rate Effects	7,145	900,722	1.1%0
Reported Biopharma Net Revenues at Constant Currency	1,419,303	1,290,382	10.0%	Reported U.S. + Canada Net Revenues at Constant Currency	986,458	968,722	1.8%
				····			
In thousands of euros	Q2 2023	Q2 2022	% Var	In thousands of euros	Q2 2023	Q2 2022	% Var
Reported Diagnostic Net Revenues	165,013	159,687	3.3%	Reported EU Net Revenues	321,871	264,855	21.5%
Variation due to Exchange Rate Effects	2,855			Variation due to Exchange Rate Effects	(87)		
Reported Diagnostic Net Revenues at Constant Currency	167,868	159,687	5.1%	Reported EU Net Revenues at Constant Currency	321,784	264,855	21.5%
In thousands of euros	Q2 2023	Q2 2022	% Var	In thousands of euros			
Reported Bio Supplies Net Revenues	40,349	28,806	40.1%		Q2 2023	Q2 2022	% Var
Variation due to Exchange Rate Effects	288			Reported ROW Net Revenues	362,274	309,323	17.1%
Reported Bio Supplies Net Revenues at Constant Currency	40.637	28.806	41.1%	Variation due to Exchange Rate Effects	8,146		
Reported Dio Supplies Net Revenues at Constant Currency	40,037	28,800	41.170	Reported ROW Net Revenues at Constant Currency	370,420	309,323	19.8%

# Net Revenue Reconciliation Constant Currency Excl. Biotest | H1 2023

In thousands of euros	H1 2023	H1 2022	% Var
Reported Net Revenues	2,967,827	2,711,805	9.4%
Variation due to Exchange Rate Effects	(46,496)		
Net Revenues at Constant Currency	2,921,331	2,711,805	7.7%
In thousands of euros	H1 2023	H1 2022	% Var
Reported Biopharma Revenues	2,441,096	2,214,603	10.2%
Variation due to Exchange Rate Effects	(41,561)		
Reported Biopharma Net Revenues at Constant Currency	2,399,535	2,214,603	8.4%
In thousands of euros	H1 2023	H1 2022	% Var
Reported U.S. + Canada Net Revenues	1,921,960	1,815,818	5.8%
Variation due to Exchange Rate Effects	(44,993)	1,015,010	5.6%
Reported U.S. + Canada Net Revenues at Constant Currency	1,876,967	1,815,818	3.4%
In thousands of euros	H1 2023	H1 2022	% Var
Reported EU Net Revenues	489,123	423,289	15.6%
Variation due to Exchange Rate Effects	(701)		
Reported EU Net Revenues at Constant Currency	488,422	423,289	15.4%
In thousands of euros	H1 2023	H1 2022	% Var
Reported ROW Net Revenues	556,744	472,698	17.8%
Variation due to Exchange Rate Effects	(802)		
Reported ROW Net Revenues at Constant Currency	555,942	472,698	17.6%



## Net Revenue Reconciliation Constant Currency Incl. Biotest | H1 2023

In thousands of euros	H1 2023	H1 2022	% Var	In thousands of euros	H1 2023	H1 2022	% Var
Reported Net Revenues	3,224,946	2,810,092	14.8%	Reported Others & Intersegments Net Revenues	102,628	115,213	(10.9%)
Variation due to Exchange Rate Effects	(45,575)			Variation due to Exchange Rate Effects	(906)		
Net Revenues at Constant Currency	3,179,371	2,810,092	13.1%	Reported Other & Intersegments Net Revenues at Constant Currency	101,722	115,213	(11.7%)
In thousands of euros	H1 2023	H1 2022	% Var	In thousands of euros	H1 2023	H1 2022	% Var
Reported Biopharma Net Revenues	2,698,215	2,312,890	16.7%	Reported U.S. + Canada Net Revenues	1,922,864	1,816,983	5.8%
Variation due to Exchange Rate Effects	(40,640)			Variation due to Exchange Rate Effects	(44,993)		
Reported Biopharma Net Revenues at Constant Currency	2,657,575	2,312,890	14.9%	Reported U.S. + Canada Net Revenues at Constant Currency	1,877,871	1,816,983	3.4%
In thousands of euros	H1 2023	H1 2022	% Var	In thousands of euros	H1 2023	H1 2022	% Var
Reported Diagnostic Net Revenues	341,488	329,436	3.7%	Reported EU Net Revenues	627,531	473,623	32.5%
Variation due to Exchange Rate Effects	(2,275)			Variation due to Exchange Rate Effects	(462)		
Reported Diagnostic Net Revenues at Constant Currency	339,213	329,436	3.0%	Reported EU Net Revenues at Constant Currency	627,069	473,623	32.4%
In thousands of euros	H1 2023	H1 2022	% Var	In thousands of euros	H1 2023	H1 2022	% Var
Reported Bio Supplies Net Revenues	82,615	52,553	57.2%	Reported ROW Net Revenues	674,551	519,486	29.8%
Variation due to Exchange Rate Effects	(1,753)			Variation due to Exchange Rate Effects	(121)		
Reported Bio Supplies Net Revenues at Constant Currency	80,862	52,553	53.9%	Reported ROW Net Revenues at Constant Currency	674,430	519,486	29.8%

# Annex Definition of Non-GAAP Measures and Constant Currency

- EBITDA is defined as operating result (EBIT), excluding depreciation of property, plant and equipment, depreciation of right-of-use assets, amortization of intangible assets, and impairments of property, plant and equipment, right-of-use assets and of intangible assets. It is used to evaluate the company's results over time, allowing it to be compared with other companies in the sector.
- Adjusted EBITDA is defined as EBITDA, excluding one-offs and items not indicative of our ongoing operating performance, including restructuring and transaction costs. It provides a useful measure for period-to-period comparisons of our business, as it removes the effect of non-recurring items.
- EBITDA LTM is defined as EBITDA related to the last 12 months.
- Adjusted EBITDA LTM is defined as Adjusted EBITDA related to the last 12 months.
- Adjusted EBITDA LTM as per Credit Agreement is defined as net income on a consolidated basis for the Group, plus (i) all financial results, (ii) any losses on ordinary course hedging obligations, (iii) any foreign currency translation, transaction or exchange losses, (iv) any loss of any equity-accounted investee, (v) tax expense, (vi) depreciation, (vii) amortization, write-offs, write-downs, and other non-cash charges, losses and expenses, (viii) impairment of intangibles, (ix) non-recurring losses, (x) transactions costs, (xi) extraordinary, unusual, or non-recurring charges and expenses including transition, restructuring and "carveout" expenses, (xii) any costs and expenses relating to the Issuer's potential or actual issuance of Equity Interests and (xiii) the amount of cost savings, adjustments, operating expense reductions, operating improvements and synergies, in each case on a "run rate" basis and in connection with acquisitions, investments, restructurings, business optimization projects and other operational changes and initiatives; less (i) interest income, (ii) non-recurring gains, (iii) any income or gains on ordinary course hedging obligations (iv) foreign currency translation, transaction or exchange gains and (v) any income of any equity-accounted investee, in each case, for the last 12 months.
- Adjusted Group Profit is defined as group profit, excluding the effect of non-cash expenses and non-recurring items not indicative of our ongoing operating performance, including restructuring and transaction costs.
- Constant currency (cc) excludes exchange rate fluctuations over the period.

# GRIFOLS

## Investor Relations & Sustainability

+34 93 571 02 21 ⊠ investors@grifols.com ⊠ sustainability@grifols.com

☑ inversores@grifols.com☑ sostenibilidad@grifols.com

